The list price of the second Remicade biosimilar, Renflexis, is 20 percent lower than that of the first Remicade biosimilar, and doctors who prescribe Renflexis would likely get a good chunk of that 20 percent difference because both biosimilars are in the same billing code, sources say. If providers widely adopt Renflexis based on the bigger profits they could make, the Medicare reimbursement for both biosimilars would drop for the rheumatoid arthritis treatments. CMS decided to group biosimilars in common...